Sustainability of Teprotumumab Efficacy in Thyroid Eye Disease
Creator
Prem S. Subramanian; Saba Sile; Robert Holt; Raymond Douglas
Affiliation
(PSS) University of Colorado, Aurora, CO; (SS) (RH) Horizon Therapeutics plc, Deerfield, IL; (RSD) Cedars Sinai Medical Center Los Angeles; Shanghai International Medical Center
Teprotumumab, an insulin-like growth factor-I receptor inhibitory antibody, improved proptosis, diplopia, inflammatory signs/symptoms, and quality of life in thyroid eye disease (TED) patients in phase 2 and 3 (OPTIC) trials.1,2 OPTIC proptosis non- responders could receive a course of teprotumumab in the OPTIC-X study. This analysis examined sustainability of response over the follow-up periods from the phase 2, OPTIC and OPTIC-X studies, including the recently proposed EUGOGO composite outcome.
Date
2022-02
Language
eng
Format
video/mp4
Type
Image/MovingImage
Source
2022 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of
NANOS Annual Meeting 2022: Scientific Platform III
